ClinicalTrials.govpublic full text
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
multiple myeloma, daratumumab, lenalidomide, dexamethasone, dose-escalation, relapsed multiple myeloma, relapsed and refractory multiple myeloma, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 898250
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.